NICE issues second ‘no’ to pomalidomide

The National Institute for Health and Care Excellence (NICE), the drug approval body for England and Wales, has issued final draft guidance that does not recommend Imnovid (pomalidomide) as a treatment for myeloma patients after third or subsequent relapse. This second negative guidance is based on their opinion that the clinical benefit of Imnovid does…

Details